In recent years, advancements in diabetes treatment have led to the introduction of new medication classes (e.g., SGLT2i and GLP1-receptor agonist, GLP-1 RA) that are not only efficacious in terms of glycemic control but also offer additional independent benefits in the prevention of cardiovascular and renal complications [3, 11]. Here, GLP1R is linked to diabetes mellitus.